📇 Rhumatologue · AUCUN · (65) · Libéral
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Praticien-chercheur
14 articles scientifiques publiés — formation continue solide
Référence presse grand public
Cité 7 fois dans les médias — pédagogie reconnue
Délais de RDV courts dans la région
122.6 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CABINET DU DR Michel RODERO
MAISON MEDICALE D'AUCUN 2 BIS ROUTE D AZUN, 65400 AUCUN
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 ladepeche.fr · 07/05/2025
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPVjFhQmVRTDdnV0pkYUlRY1U1SmtocG0yQUVWN1VmLW1CZEtnRzRYeXBGRl85dmFtMk9LUzQ5UzA2SFRhMGluRjY2aU1INjRQZndoVHVjR3d3WC1FZTFxVWxYYlhzV1ZURFBpUktuUDFjcTFfSVJHRnFXTTJFQS11bmJYNUJ5OUJqN2JTdzRYVEp0UzdSSXAzYnlMVEowSUk?oc=5" target="_blank">Aucun. Un bi
📰 ladepeche.fr · 15/05/2024
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPWGtfcE0tNEZSaWc0UE1FemM3UUZ3S3d1eXpsWDUyckdxTTlBNC10dkFNZWtHV21BSzZSV3lxN19lbzI3RHp6c015cEpaSTVFNC1UWXR2T3cyS1MwVWxhSlJGUG5qSXozcDUxdGNsTnZ1MUFJN3RzQURhaExwVWg2WjlqWmxwOTg5VHpqS0ZLbXRqMUxrdVJkUWFWQjROVnph?oc=5" target="_blank">Arrens-Mars
📰 Actu.fr · 11/01/2024
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxPU0lVMkNNRTZmUng0WklYdW93bENIcjRoSDZyWEI1bGY4TFZ2cms1NVRwOUJSNnB5X3FBckM0RzZGcjVwOW9yc2NWRVV4T2VFSHhDMHRLNTByV093UjRvZ2hnYnFXRVZhN0FqMnlGWHktMC1LV3pNdDd5YTc4T2JHOFpnRVM1b3RtT1dVY1JiSEp0ZUVYeTVldnFLN0VaNjljbjFhWUp4QVA3b3JUR1ptQk9XeVBBb1pSaX
📰 BFM · 10/01/2024
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQblJrWnJUVmdaV3JoNk9ubk9ORGN5OUNUUmVVWXJybGlMX0YzNzJZTVZYYTl0QkZEZUNuc052T1JLR010OXFEczd2VTI3OWhCcFZjekdZLTFpckpEZjMweHFyQ0xVVHpKcVJpVTd2U3pnd1hPY05RWTN0a0NiWlRGLWFfWVFyYzhYcGR1VzNmRXc0Q0szNnhySG9IdGs1N3hBOWtKYnNYbk0zWENXWjM5MDBuUmlORUlVeF
📰 BFM · 10/01/2024
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxPRzRaZGN2cGVvOXdhdU03RmFtR3pMQUVJTEg3MG8xZFlQbElUSzhRalNUNkN3Znk0SmlvamcyZlJ0aEJMRm12WHhVZzZsS1VDVDYtR0lsZVFDRnd0YTJHaWdOVDlDT1hncUY2ZS1FbFpzSGV0ZE9WcHoyS3NZTTVIUUJxdldsYy1jQ0t5Nmk5TjIwNTVIT3NYdGNINjdEVFBBbURBQ2Y2ZlNhS1NmXy0tdGZDNUJkbTFjeH
📰 France 3 Régions · 04/01/2024
<a href="https://news.google.com/rss/articles/CBMilAJBVV95cUxOT0UwNVRUZy13OEtPekxQVDBWb2p6eXA5Y2h3ZzVZd3dabkJWYmg2cUdvMVc0MWI0S1d4REdMSzB6QVRpVkxKRmU4QWN0R2VYQ1pBT3h5eUVoRnFuRHVRRGFsUWtsVjlnZWZGaUF1NHh3MWxCUkxUZzMyWTlYSndwbVNuVzl3SFktbmpiaGY1bGRLZ08wZ0hqQ0VkZGNoeEhWcmxORFdILUJDTkNkRmtTRTJyUzlRdVRMeD
📰 NRPyrenees.fr · 02/01/2024
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxPbHRNeWxzMUl5NTczQnlzMzkxdUtQRHV6SzRtSE9JaENrcW9uX3ByYm1xdXAwQW9PVGFycy1PelJ3azVkak5mZi12TEk4SXVkWTlocFJUNEtUbVpzemZ3YWl1SGZqeG5zWWxQdWxKT19vdW1SeUx2bnY5QlhWbEx3VFY0Z3poLVZwVzB2TmkxRTNfVDVzbUZlUE5tWm5RbXJTTDN3Y3UzX0xVNlRySVJNQ1I3ZS1EQXpUcU
The Journal of experimental medicine · 2016
Type I interferon is a potent substance. As such, the induction, transmission, and resolution of the type I interferon–mediated immune response are tightly regulated. As defined, the type I interferonopathies represent discrete examples of a disturbance of the homeostatic control of this system caused by Mendelian mutations. Considering the complexity of the interferon response, the identification of further monogenic diseases belonging to this disease grouping seems likely, with the recognition of type I interferonopathies becoming of increasing clinical importance as treatment options are developed based on an understanding of disease pathology and innate immune signaling. Definition of the type I interferonopathies indicates that autoinflammation can be both interferon and noninterferon related, and that a primary disturbance of the innate immune system can “spill over” into autoimmunity in some cases. Indeed, that several non-Mendelian disorders, most particularly systemic lupus erythematosus and dermatomyositis, are also characterized by an up-regulation of type I interferon signaling suggests the possibility that insights derived from this work will have relevance to a broader field of clinical medicine.
The Journal of experimental medicine · 2017
Type I interferons (IFNs) are essential mediators of antiviral responses. These cytokines have been implicated in the pathogenesis of autoimmunity, most notably systemic lupus erythematosus (SLE), diabetes mellitus, and dermatomyositis, as well as monogenic type I interferonopathies. Despite a fundamental role in health and disease, the direct quantification of type I IFNs has been challenging. Using single-molecule array (Simoa) digital ELISA technology, we recorded attomolar concentrations of IFNα in healthy donors, viral infection, and complex and monogenic interferonopathies. IFNα protein correlated well with functional activity and IFN-stimulated gene expression. High circulating IFNα levels were associated with increased clinical severity in SLE patients, and a study of the cellular source of IFNα protein indicated disease-specific mechanisms. Measurement of IFNα attomolar concentrations by digital ELISA will enhance our understanding of IFN biology and potentially improve the diagnosis and stratification of pathologies associated with IFN dysregulation.
Journal of clinical immunology · 2015
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Frontiers in immunology · 2023 · Journal Article
Bekaddour N, Smith N, Beitz B, Llibre A, et al.
Biomedicines · 2023 · Journal Article
Mohamed Mohamed K, Álvarez-Hernández MP, Jiménez García C, Guevara-Hoyer K, et al.
Reumatologia clinica · 2022 · Journal Article
Castañeda S, González C, Villaverde V, Lajas Petisco C, et al.
Reumatologia clinica · 2020 · Journal Article
Castañeda S, González C, Villaverde V, Lajas Petisco C, et al.
Science advances · 2019 · Journal Article
Smith N, Rodero MP, Bekaddour N, Bondet V, et al.
The Journal of experimental medicine · 2017 · Journal Article
Rodero MP, Decalf J, Bondet V, Hunt D, et al.
The Journal of experimental medicine · 2016 · Journal Article
Rodero MP, Crow YJ
Journal of clinical immunology · 2015 · Journal Article
Rice GI, Rodero MP, Crow YJ
Rheumatology (Oxford, England) · 2022 · Journal Article
Dabbak I, Rodero MP, Aeschlimann FA, Authier FJ, et al.
Frontiers in immunology · 2020 · Journal Article
Gies V, Bekaddour N, Dieudonné Y, Guffroy A, et al.
Rheumatology (Oxford, England) · 2020 · Journal Article
Melki I, Devilliers H, Gitiaux C, Bondet V, et al.
RMD open · 2016 · Journal Article
Uettwiller F, Sarrabay G, Rodero MP, Rice GI, et al.
Journal of clinical immunology · 2017 · Journal Article
Rice GI, Melki I, Frémond ML, Briggs TA, et al.
Reumatologia clinica · 2023 · Systematic Review
Lois P, López Pedraza L, Rodero M, Mulero T, et al.